16 February 2023Three-dimensional (3D) total-body photography is a recent advance in melanoma early detection that can aid in monitoring and identifying new and changing skin lesions over time. Participant feedback indicated a high level of acceptance and confidence in the technology. To facilitate clinical translation, addressing consumer-identified barriers to 3D total-body photography will be vital.
16 February 2023The objective of this narrative review is to describe current and ongoing research in the use of topical photosensitizers and modified light delivery regimens to achieve improved therapeutic outcomes with less toxicity in patients with actinic keratoses, cutaneous squamous cell carcinomas, basal cell carcinomas, and field cancerization.
16 February 2023Authors of this recent study propose that the inner nuclear membrane proteinLAP1 renders the nucleus highly adaptable and contributes to melanoma aggressiveness.
15 February 2023Authors of this study state that the implementation of the newly revised MPATH-Dx version 2.0 schema into clinical practice is anticipated to provide a robust tool and adjunct for standardized diagnostic reporting of melanocytic lesions and management of patients to the benefit of both health care practitioners and patients.
14 February 2023According to this recent study, the patient population undergoing isolated limb perfusion (ILP) for in-transit melanoma is largely unchanged in the current era of effective systemic treatments. Response rates have not decreased, and prior immune checkpoint inhibitors (ICI) treatment did not affect response rates, making ILP still a valid treatment option for this patient group.
14 February 2023This review discusses recent findings in melanoma phenotype switching, immunotherapy resistance, and the balancing of the homeostatic tumor microenvironment between the different melanoma cell subpopulations. Authors also discuss future perspectives of the biology of neural crest-like state(s) in melanoma.
14 February 2023According to this recent study, there is rapid, consistent, and accumulating evidence generated from trials, indicating clinical superiority of neoadjuvant immunotherapy over adjuvant systemic therapy for macroscopic stage III melanoma.
14 February 2023This review provides an overview of the cellular pathways of pyroptosis and discusses the therapeutic potential of pyroptosis induction in cancer, particularly in melanoma.
14 February 2023Data of this recent study suggest the applicability of ascorbate as an additional therapeutic agent that can be safely combined with immunotherapy and has the potential to potentiate anti-PD1-based immune checkpoint blockades.
14 February 2023According to this recent study, immune checkpoint inhibitors (ICIs) had comparable efficacy between younger and older patients, although outcomes were superior with combination ICI compared to monotherapy in patients aged ≤40 years. Toxicity incidence was similar across age groups, though organs affected were substantially different.
